Robert LeBoyer, an analyst from Noble Financial, has initiated a new Buy rating on Zomedica Pharmaceuticals (ZOM). Robert LeBoyer’s …
Zomedica Positioned for Growth with Strategic Acquisitions and Strong Financial Performance: Buy Recommendation
view original post